Biotinylated Delta Variant Spike RBD SARS-CoV-2

• Description:

  Biotinylated Delta Variant Spike RBD SARS-CoV-2  _x000D_ Catalog number: B2010481_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 25 ug_x000D_ Molecular Weight or Concentration: 27 kDa_x000D_ Supplied as: Buffered Solution_x000D_ Appearance: Solution_x000D_ Applications: highly pure (> 95%) biotinylated SARS-CoV-2 RBD of the Delta Variant. This protein was expressed in HEK293, biotinylated in vitro and tested for its ability to bind the human cellular receptor ACE2._x000D_ Storage: -20C_x000D_ Keywords: Biotin RBD, Biotin Delta RBD_x000D_ Grade: Biotechnology grade. All solid components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ Download SARS-CoV-2 Brochure_x000D_ _x000D_ References:_x000D_ 1: Bertoglio F, Fühner V, Ruschig M, Heine PA, Abassi L, Klünemann T, Rand U,_x000D_ Meier D, Langreder N, Steinke S, Ballmann R, Schneider KT, Roth KDR, Kuhn P,_x000D_ Riese P, Schäckermann D, Korn J, Koch A, Chaudhry MZ, Eschke K, Kim Y, Zock-_x000D_ Emmenthal S, Becker M, Scholz M, Moreira GMSG, Wenzel EV, Russo G, Garritsen_x000D_ HSP, Casu S, Gerstner A, Roth G, Adler J, Trimpert J, Hermann A, Schirrmann T,_x000D_ Dübel S, Frenzel A, Van den Heuvel J, ÄŒičin-Å ain L, Schubert M, Hust M. A SARS-_x000D_ CoV-2 neutralizing antibody selected from COVID-19 patients binds to the_x000D_ ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Rep. 2021_x000D_ Jul 27;36(4):109433._x000D_ _x000D_ 2: Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes_x000D_ BF, Sanders KO, Gnanakaran S, Hengartner N, Pajon R, Smith G, Glenn GM, Korber_x000D_ B, Montefiori DC. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing_x000D_ antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 2021 Apr_x000D_ 14;29(4):529-539.e3._x000D_ _x000D_ 3: Ou J, Zhou Z, Dai R, Zhang J, Zhao S, Wu X, Lan W, Ren Y, Cui L, Lan Q, Lu L,_x000D_ Seto D, Chodosh J, Wu J, Zhang G, Zhang Q. V367F Mutation in SARS-CoV-2 Spike_x000D_ RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity_x000D_ through Increased Human ACE2 Receptor Binding Affinity. J Virol. 2021 Jul_x000D_ 26;95(16):e0061721._x000D_ _x000D_ 4: Pymm P, Adair A, Chan LJ, Cooney JP, Mordant FL, Allison CC, Lopez E,_x000D_ Haycroft ER, O'Neill MT, Tan LL, Dietrich MH, Drew D, Doerflinger M, Dengler MA,_x000D_ Scott NE, Wheatley AK, Gherardin NA, Venugopal H, Cromer D, Davenport MP,_x000D_ Pickering R, Godfrey DI, Purcell DFJ, Kent SJ, Chung AW, Subbarao K, Pellegrini_x000D_ M, Glukhova A, Tham WH. Nanobody cocktails potently neutralize SARS-CoV-2 D614G_x000D_ N501Y variant and protect mice. Proc Natl Acad Sci U S A. 2021 May_x000D_ 11;118(19):e2101918118._x000D_ _x000D_ 5: Gobeil SM, Janowska K, McDowell S, Mansouri K, Parks R, Stalls V, Kopp MF,_x000D_ Manne K, Saunders K, Edwards RJ, Haynes BF, Henderson RC, Acharya P. Effect of_x000D_ natural mutations of SARS-CoV-2 on spike structure, conformation and_x000D_ antigenicity. bioRxiv [Preprint]. 2021 Mar 15:2021.03.11.435037._x000D_ _x000D_ 6: Khan A, Wei DQ, Kousar K, Abubaker J, Ahmad S, Ali J, Al-Mulla F, Ali SS,_x000D_ Nizam-Uddin N, Mohammad Sayaf A, Mohammad A. Preliminary Structural Data_x000D_ Revealed That the SARS-CoV-2 B.1.617 Variant's RBD Binds to ACE2 Receptor_x000D_ Stronger Than the Wild Type to Enhance the Infectivity. Chembiochem. 2021 Aug_x000D_ 17;22(16):2641-2649._x000D_ _x000D_ 7: Tsai MS, Yang YH, Lin YS, Chang GH, Hsu CM, Yeh RA, Shu LH, Cheng YC, Liu HT,_x000D_ Wu YH, Wu YH, Shen RC, Wu CY. GB-2 blocking the interaction between ACE2 and_x000D_ wild type and mutation of spike protein of SARS-CoV-2. Biomed Pharmacother. 2021_x000D_ Aug 5;142:112011._x000D_ _x000D_ 8: Gobeil SM, Janowska K, McDowell S, Mansouri K, Parks R, Stalls V, Kopp MF,_x000D_ Manne K, Li D, Wiehe K, Saunders KO, Edwards RJ, Korber B, Haynes BF, Henderson_x000D_ R, Acharya P. Effect of natural mutations of SARS-CoV-2 on spike structure,_x000D_ conformation, and antigenicity. Science. 2021 Aug 6;373(6555):eabi6226._x000D_ _x000D_ 9: Deshpande A, Harris BD, Martinez-Sobrido L, Kobie JJ, Walter MR. Epitope_x000D_ Classification and RBD Binding Properties of Neutralizing Antibodies Against_x000D_ SARS-CoV-2 Variants of Concern. Front Immunol. 2021 Jun 4;12:691715._x000D_ 10: McCallum M, Bassi J, De Marco A, Chen A, Walls AC, Di Iulio J, Tortorici MA,_x000D_ Navarro MJ, Silacci-Fregni C, Saliba C, Sprouse KR, Agostini M, Pinto D, Culap_x000D_ K, Bianchi S, Jaconi S, Cameroni E, Bowen JE, Tilles SW, Pizzuto MS, Guastalla_x000D_ SB, Bona G, Pellanda AF, Garzoni C, Van Voorhis WC, Rosen LE, Snell G, Telenti_x000D_ A, Virgin HW, Piccoli L, Corti D, Veesler D. SARS-CoV-2 immune evasion by the_x000D_ B.1.427/B.1.429 variant of concern. Science. 2021 Aug 6;373(6555):648-654. _x000D_ _x000D_ Products Related to Delta Variant SARS-CoV-2 Spike RBD Biotinylated : SARS-CoV-2

• Short Description:

  Catalog Number: B2010481 (25 ug)_x000D_ Delta Variant SARS-CoV-2 Spike RBD Biotinylated is a highly pure (> 95%) biotinylated SARS-CoV-2 RBD of the Delta Variant. This protein was expressed in HEK293, biotinylated in vitro and tested for its ability to bind the human cellular receptor ACE2. Custom bulk orders of this product are available upon request._x000D_

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height :

  0.5